Reaktionsgleichung
C(OC([NH:11][C@H:12]1[CH2:17][CH2:16][N:15]([C:18]2[CH:19]=[C:20]([CH:25]=[CH:26][CH:27]=2)[C:21]([O:23][CH3:24])=[O:22])[CH2:14][C@H:13]1[O:28][CH3:29])=O)C1C=CC=CC=1>[C].[Pd]>[NH2:11][C@H:12]1[CH2:17][CH2:16][N:15]([C:18]2[CH:19]=[C:20]([CH:25]=[CH:26][CH:27]=2)[C:21]([O:23][CH3:24])=[O:22])[CH2:14][C@H:13]1[O:28][CH3:29]Komponenten
3
Versuchsvorschrift
The same operation as in Example (160c) was performed using methyl cis(±)-3-(4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidin-1-yl)benzoate obtained in Example (42a) (180 mg) and a 10% palladium-carbon catalyst (150 mg), to obtain 104.5 mg of the title compound as a white solid. The resulting compound was used for the next reaction without purification.
Quellen und Nachweise
- ORD-Eintrag
- ord-e4d7c9fea97e43ada9361d3a3512a57a
- Quelldatensatz
- uspto-grants-2013_09
- Patentnummer
- US08536197B2
Verknüpfte Notizen
Wird geladen…